NeoStem presents five-year survival data for autologous melanoma Immunotherapy NeoStem announced results of a pooled analysis indicating that Melapuldencel-T, an investigational patient-specific immunotherapy for metastatic melanoma, may increase survival rates significantly for patients at the most advanced stages of the disease.
http://ift.tt/1ws6FTQ
http://ift.tt/1ws6FTQ
No comments:
Post a Comment